Twist Bioscience Prices Upsized $300M Offering at $96/Share as Underwriters Exercise Full Option
TWST has more than doubled off its 52-week low of $23.3 on elevated volume (1.9× avg).
Summary
Twist Bioscience priced an upsized $300 million public offering at $96 per share, with underwriters exercising their full option for an additional 468,750 shares, bringing total net proceeds to ~$327.1 million. The offering, increased from $250 million due to strong demand, will fund R&D and manufacturing expansion.
Key Events · Financing and Capital Events · TWST
-
Upsized Offering Priced at $96/Share
Twist priced 3.125 million shares at $96.00 each, raising $300 million in gross proceeds — a 20% increase from the initially proposed $250 million offering.
-
Underwriters Exercise Full Option
The underwriters exercised their option to purchase an additional 468,750 shares at $96.00, bringing total shares sold to 3,593,750 and net proceeds to approximately $327.1 million after fees.
-
Use of Proceeds for Growth
Net proceeds will fund R&D investments, manufacturing capacity expansion, product offerings, and general corporate purposes, extending the company's cash runway.
-
Offering Closes August 6, 2026
The transaction is expected to close on August 6, 2026, subject to customary conditions, with a 60-day lock-up period for the company and certain shareholders.
Analysis · TWST · Life Sciences
Twist Bioscience finalized an upsized public offering, selling 3.125 million shares at $96.00 each — a 20% increase from the initially proposed $250 million. The underwriters immediately exercised their full option for an additional 468,750 shares, bringing total gross proceeds to $300 million and net proceeds to approximately $327.1 million. While the offering price represents a modest discount to the current $115.00 stock price, the rapid upsizing and full option exercise signal strong institutional demand. The capital raise significantly strengthens the balance sheet, funding R&D and manufacturing expansion, but dilutes existing shareholders by roughly 5-6% based on the company's market cap. This follows a series of insider sales and a recent ATM program, yet the offering's execution near a 52-week high and the demand-driven upsizing suggest the market views the raise as growth-oriented rather than distressed.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 40.1% of the 1118 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $115.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $23.30 to $115.56. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.